Lataa...
SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis()
INTRODUCTION: The effect of SARS-CoV-2 infection in patients with multiple sclerosis (MS) and the influence of disease-modifying therapies (DMT) for MS on COVID-19 are unknown. To date, patients with MS have not been shown to present greater risk of COVID-19 or more severe progression of the disease...
Tallennettuna:
| Julkaisussa: | Neurologia (Engl Ed) |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Sociedad Española de Neurología. Published by Elsevier España, S.L.U.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8166535/ https://ncbi.nlm.nih.gov/pubmed/34103271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nrleng.2021.03.002 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|